Contrasting Imunon (NASDAQ:IMNN) and Liminatus Pharma (NASDAQ:LIMN)

Liminatus Pharma (NASDAQ:LIMN) and Imunon (NASDAQ:IMNN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Earnings & Valuation

This table compares Liminatus Pharma and Imunon”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21 million	($0.47)	-9.38
Imunon	N/A	N/A	-$14.49 million	($3.83)	-0.43

Liminatus Pharma is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Liminatus Pharma and Imunon, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1	0	0	0	1.00
Imunon	1	0	1	0	2.00

Imunon has a consensus target price of $10.00, suggesting a potential upside of 513.50%. Given Imunon’s stronger consensus rating and higher possible upside, analysts clearly believe Imunon is more favorable than Liminatus Pharma.

Profitability

This table compares Liminatus Pharma and Imunon’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-256.58%
Imunon	N/A	-358.01%	-132.91%

Insider and Institutional Ownership

4.5% of Imunon shares are held by institutional investors. 19.4% of Liminatus Pharma shares are held by insiders. Comparatively, 2.8% of Imunon shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Liminatus Pharma has a beta of 5.35, suggesting that its share price is 435% more volatile than the S&P 500. Comparatively, Imunon has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500.

Summary

Liminatus Pharma beats Imunon on 6 of the 11 factors compared between the two stocks.

About Liminatus Pharma

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

About Imunon

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon’s DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.